JWCTF (JW (Cayman) Therapeutics Co) Total Assets: $140.12 Mil (As of Dec. 2025)


JWCTF JW (Cayman) Therapeutics Co Ltd JWCTF
28 GF Score
Price $0.23
GF Value $0.57
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is JW (Cayman) Therapeutics Co Total Assets?

JW (Cayman) Therapeutics Co JWCTF -1.85% 28 Total Assets is $140.12 Mil as of Dec. 2025. GuruFocus rates JWCTF with a GF Score™ of 28/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 3 warning signs investors should review.

JW (Cayman) Therapeutics Co's Total Assets for the quarter that ended in Dec. 2025 was $140.12 Mil.

During the past 12 months, JW (Cayman) Therapeutics Co's average Total Assets Growth Rate was -45.80% per year. During the past 3 years, the average Total Assets Growth Rate was -30.20% per year. During the past 5 years, the average Total Assets Growth Rate was -16.50% per year.

During the past 8 years, JW (Cayman) Therapeutics Co's highest 3-Year average Total Assets Growth Rate was 88.30%. The lowest was -30.20%. And the median was -2.90%.

Total Assets is connected with ROA %. JW (Cayman) Therapeutics Co's annualized ROA % for the quarter that ended in Dec. 2025 was -48.42%. Total Assets is also linked to Revenue through Asset Turnover. JW (Cayman) Therapeutics Co's Asset Turnover for the quarter that ended in Dec. 2025 was 0.15.

JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) Total Assets Explanation

Total Assets is connected with ROA %.

JW (Cayman) Therapeutics Co's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-81.788/( (197.683+140.12)/ 2 )
=-81.788/168.9015
=-48.42 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

JW (Cayman) Therapeutics Co's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=25.174/( (197.683+140.12)/ 2 )
=25.174/168.9015
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

JW (Cayman) Therapeutics Co Total Assets Related Terms

JW (Cayman) Therapeutics Co Total Assets Historical Data

* Premium members only.

The historical data trend for JW (Cayman) Therapeutics Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co Total Assets Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 489.32 400.38 300.57 230.80 140.12

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 300.57 272.90 230.80 197.68 140.12
JWCTF
28GF Score
JW (Cayman) Therapeutics Co Ltd JWCTF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

JW (Cayman) Therapeutics Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

JW (Cayman) Therapeutics Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=78.978+61.142
=140.12

JW (Cayman) Therapeutics Co's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=78.978+61.142
=140.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $140.12 Mil mean?
JW (Cayman) Therapeutics Co (JWCTF) has a Total Assets of $140.12 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on JW (Cayman) Therapeutics Co and its competitors.
Is JW (Cayman) Therapeutics Co's Total Assets too high?
JW (Cayman) Therapeutics Co's current Total Assets is $140.12 Mil. Overall, JW (Cayman) Therapeutics Co has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JW (Cayman) Therapeutics Co's Total Assets compare to VRTX and REGN?
JW (Cayman) Therapeutics Co's Total Assets of $140.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on JW (Cayman) Therapeutics Co and its competitors. JW (Cayman) Therapeutics Co's current Total Assets is $140.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JW (Cayman) Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co (JWCTF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.23 — trading 59.1% below its estimated fair value. The current Total Assets is $140.12 Mil. JW (Cayman) Therapeutics Co's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For JW (Cayman) Therapeutics Co (JWCTF), the current Total Assets is $140.12 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is JW (Cayman) Therapeutics Co (JWCTF) Overvalued in 2026?

Based on GuruFocus' analysis, JW (Cayman) Therapeutics Co stock appears to be undervalued. The current stock price of $0.23 is trading 59.1% below its estimated GF Value™ of $0.57. GuruFocus considers JW (Cayman) Therapeutics Co to be Possible Value Trap.

Key valuation signals for JWCTF:

  • Total Assets: $140.12 Mil
  • GF Value™: $0.57 vs. price of $0.23 (59.1% below fair value)
  • GF Score™: 28/100 with 3 warning signs

No single metric tells the full story. See the JWCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

JW (Cayman) Therapeutics Co Business Description

Other Exchanges 02126:Hong KongJNY:Germany
Address No. 699 Zhong Ke Road, 5th Floor, Building B, Wison Center, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
28GF Score

Get the complete analysis for JWCTF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.23
Price
$0.57
GF Value